Last reviewed · How we verify
Furosemide dose escalation
Furosemide is a loop diuretic that inhibits sodium and chloride reabsorption in the ascending limb of the loop of Henle, promoting increased urine output and fluid elimination.
Furosemide is a loop diuretic that inhibits sodium and chloride reabsorption in the ascending limb of the loop of Henle, promoting increased urine output and fluid elimination. Used for Edema associated with congestive heart failure, Edema associated with hepatic cirrhosis, Edema associated with renal disease.
At a glance
| Generic name | Furosemide dose escalation |
|---|---|
| Also known as | Lasix |
| Sponsor | University of North Carolina, Chapel Hill |
| Drug class | Loop diuretic |
| Target | Na-K-2Cl cotransporter (NKCC2) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Furosemide blocks the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, preventing reabsorption of sodium, potassium, and chloride. This results in increased osmotic pressure in the tubular lumen, reducing water reabsorption and producing a potent diuretic effect. Dose escalation refers to titrating the dose upward to achieve desired diuretic response in patients with fluid overload or edema.
Approved indications
- Edema associated with congestive heart failure
- Edema associated with hepatic cirrhosis
- Edema associated with renal disease
- Hypertension
Common side effects
- Hypokalemia
- Hyperuricemia
- Ototoxicity (at high doses)
- Dehydration
- Hypotension
- Hyperglycemia
- Hyponatremia
Key clinical trials
- Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (PHASE1, PHASE2)
- To Assess the Efficacy of Midodrine in Prevention of Cirrhosis Related Complications in Children Awaiting Liver Transplantation. (NA)
- Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients (PHASE1, PHASE2)
- Pilot Study of Loop Diuretics Among Individuals Receiving Hemodialysis (PHASE2)
- Systematic Escalation of diuREtics With Natriuresis in Heart Failure Patients: SERENA Trial (PHASE3)
- Efficacy of Targeted And Response-Guided Albumin Therapy Versus Standard Medical Treatment In Outcomes Of Recurrent Ascites In Patients With Decompensated Cirrhosis. (NA)
- Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure (PHASE4)
- Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Furosemide dose escalation CI brief — competitive landscape report
- Furosemide dose escalation updates RSS · CI watch RSS
- University of North Carolina, Chapel Hill portfolio CI